Sesen Bio IncNASDAQ:SESNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6002
- TODAY'S CHANGE (%)0.0124 (2.1096%)
- Bid / Lots0.6001/ 1
- Ask / Lots0.6060/ 21
- Open / Previous Close0.6000 / 0.5878
- Day Range
- 52 Week Range
- Volume296,205
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SESN |
|---|---|---|
| 09:32 ET | 4315 | 0.5851 |
| 09:35 ET | 3700 | 0.585607 |
| 09:37 ET | 13250 | 0.5937 |
| 09:42 ET | 30300 | 0.5887 |
| 09:44 ET | 25100 | 0.5861 |
| 09:46 ET | 700 | 0.5929 |
| 09:50 ET | 20100 | 0.5999 |
| 09:53 ET | 100 | 0.5944 |
| 09:55 ET | 5000 | 0.593 |
| 09:57 ET | 26425 | 0.593 |
| 10:00 ET | 12726 | 0.593 |
| 10:06 ET | 100 | 0.5976 |
| 10:08 ET | 5802 | 0.595 |
| 10:11 ET | 156 | 0.599899 |
| 10:13 ET | 20700 | 0.5975 |
| 10:15 ET | 100 | 0.595 |
| 10:20 ET | 9545 | 0.5974 |
| 10:22 ET | 14100 | 0.5999 |
| 10:24 ET | 8625 | 0.5931 |
| 10:26 ET | 100 | 0.59655 |
| 10:31 ET | 100 | 0.5931 |
| 10:36 ET | 100 | 0.5975 |
| 10:38 ET | 6200 | 0.599 |
| 10:40 ET | 200 | 0.6 |
| 10:42 ET | 918 | 0.599 |
| 10:44 ET | 1116 | 0.5999 |
| 10:45 ET | 10228 | 0.5982 |
| 10:47 ET | 2080 | 0.6098 |
| 10:49 ET | 500 | 0.6095 |
| 10:51 ET | 15225 | 0.6 |
| 10:54 ET | 700 | 0.6094 |
| 10:56 ET | 2300 | 0.60475 |
| 10:58 ET | 300 | 0.6094 |
| 11:00 ET | 1442 | 0.6013 |
| 11:02 ET | 300 | 0.61 |
| 11:03 ET | 41350 | 0.6099 |
| 11:05 ET | 400 | 0.606 |
| 11:07 ET | 7000 | 0.6001 |
| 11:09 ET | 600 | 0.6002 |
Yesterday
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger, from 18 hours ago by Business Wire
18 hours ago by Business WireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANGN, SAFE, SESN, LMST, from 11:04AM ET on Thursday Feb 02, 2023 by PR Newswire
11:04AM ET on Thursday Feb 02, 2023 by PR Newswire
Feb 1, 2023
SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing Investigations, from 4:21PM ET on Wednesday Feb 01, 2023 by PR Newswire
4:21PM ET on Wednesday Feb 01, 2023 by PR Newswire
Jan 30, 2023
Sesen Bio Receives Nasdaq Delisting Notice, Plans to Request Hearing, from 10:37AM ET on Monday Jan 30, 2023 by MT Newswires
10:37AM ET on Monday Jan 30, 2023 by MT NewswiresBRIEF-Sesen Bio Receives Nasdaq Delisting Notice, from 9:37AM ET on Monday Jan 30, 2023 by Thomson Reuters
9:37AM ET on Monday Jan 30, 2023 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sesen Bio Inc | 119.2M | -35.5x | --- |
MDxHealth SA | 114.2M | 0.0x | --- |
Syros Pharmaceuticals Inc | 103.6M | -0.3x | --- |
Sol Gel Technologies Ltd | 129.0M | 30.1x | --- |
F-Star Therapeutics Inc | 107.7M | -2.4x | --- |
Celularity Inc | 135.2M | -5.6x | --- |
Company Information
Sesen Bio, Inc. is a late-stage clinical company engaged in advancing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
Contact Information
- Headquarters
- 245 1st St Ste 1800CAMBRIDGE, MA, United States 02142-1292
- Phone
- 617-444-8550
- Fax
- 617-858-0911
Executives
- Independent Chairman of the Board
- Jay Duker
- President, Chief Executive Officer, Director
- Thomas Cannell
- Chief Financial Officer, Treasurer
- Monica Forbes
- Chief Technology Officer
- Glen MacDonald
- Chief Accounting Officer, Controller
- Elly Ryu
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $119.2M |
|---|---|
Revenue (TTM) | $60.0M |
Shares Outstanding | 202.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.82 |
EPS | $-0.02 |
Book Value | $0.86 |
P/E Ratio | -35.5x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -13.49% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
